Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1H MRS) in children with Down syndrome

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1070-1077

  Śmigielska Kuzia, Joanna ^a   Boćkowski, Leszek ^a   Sobaniec, Wojciech ^a   Kułak, Wojciech ^a   Sendrowski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Down syndrome; Magnetic resonance spectroscopy; Temporal lobes

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; NEUROTRANSMITTER;

ADOLESCENT; AMINO ACID METABOLISM; ARTICLE; BRAIN METABOLISM; CHILD; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FRONTAL LOBE; HUMAN; MALE; METABOLIC DISORDER; METABOLITE; NEUROIMAGING; PATIENT ASSESSMENT; PRESCHOOL CHILD; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL LOBE;

EID: 79551485137     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70369-8     Document Type: Article

References (31)

1. Beacher F, Simmons A, Daly E, Prasher V, Adams C, Margallo-Lana ML, Morris R et al.: Hippocampal myoinositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Arch Gen Psychiatry, 2005, 62, 1360-1365. (Pubitemid 41746613)
2. Berry GT, Wang ZJ, Dreha SF, Finucane BM, Zimmerman RA: In vivo brain myo-inositol levels in children with Down syndrome. J Pediatr, 1999, 135, 94-97.
3. Braak H, Braak E: Neuropathological staging of Alzheimer's disease. Acta Neuropathol, 1991, 82, 239-259.
4. Danysz W, Zaja̧czkowski W, Parsons CG: Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol, 1995, 6, 455-474.
5. Demougeot C, Marie C, Giroud M, Beley A: N-Acetylaspartate: a literature review of animal research on brain ischaemia. J Neurochem, 2004, 90, 776-783.
6. Du AT, Schuff N, Amend D, Laakso MP: Magnetic resonance imaging of the entorhial cotex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry, 2001, 71, 441-447.
7. Fellini L, Florian C, Courtney J, Roullet P: Pharmacological intervention of hippocampal CA3 NMDA receptors impairs acquisition and long-term memory retrieval of spatial pattern completion task. Learn Mem, 2009, 16, 387-394.
8. Gerli G, Zenoni L, Locatelli GF, Mongiat R, Piattoni F, Orsini GB, Montagnani A et al.: Erythrocyte antioxidant system in Down syndrome. Am J Med Genet, Suppl, 1990, 7, 272-273.
9. Hashimoto T, Tayama M, Miyazaki M, Yoneda Y, Yoshimoto T, Harada M, Miyoshi H et al.: Reduced N-acetylaspartate in the brain observed on in vivo proton magnetic resonance spectroscopy in patients with mental retardation. Pediatr Neurol, 1995, 13, 205-208.
10. Hsu Yuan-Yu, Du An-Tao, Schuff N, Weiner MW: Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. J Geriatr Psychiatr Neurol, 2001, 14, 145-166. (Pubitemid 32830417)
11. 1H MRS study. Am J Psychiatry, 1999, 156, 1879-1886.
12. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R et al.: Proton MR spectroscopy detectes a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology, 2000, 55, 684-688.
13. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Psychol Soc, 2002, 8, 934-942.
14. Kesslak JP, Nagata SF, Lott I, Nalcioglu O: Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down's syndrome. Neurology, 1994, 44, 1039-1045.
15. Kułak W, Sobaniec W, Kubas B, Walecki J: Proton magnetic resonance spectroscopy in children with spastic diplegia. Neurosci Lett, 2004, 636, 62-64. (Pubitemid 38639852)
16. Kułak W, Sobaniec W, OEmigielska-Kuzia J, Kubas B, Boćkowski L: Neurophysiologic and neuroimaging studies of brain plasticity in children with spastic cerebral palsy. Exp Neurol, 2006, 198, 4-11.
17. Mann DM: Alzheimer's disease and Down's syndrome: Histopathology, 1988, 13, 125-127.
18. Murata T, Koshino Y, Omori M, Murata I, Nishio M, Horie T, Umezawa Y et al.: In vivo proton magnetic resonance spectroscopy study on premature aging in adult Down's syndrome. Biol Psychiatry, 1993, 1, 290-297.
19. Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep, 2008, 60, 692-698.
20. Orrego F, Villanueva S: The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience, 1993, 56, 539-555.
21. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, Gobbi G et al.: Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev, 1997, 97, 9-14.
22. Patel P, Goldberg D, Moss S: Psychiatric morbidity in older people with moderate and severe learning disability. II: The prevalence study. Br J Psychiatry, 1993, 163, 481-491. (Pubitemid 23297465)
23. 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging, 1999, 17, 291-299.
24. Shonk T, Ross BD: Role of increased cerebral myoinositol in the dementia of Down syndrome. Magn Reson Med, 1995, 33, 858-861.
25. Sobaniec W: Lipid peroxidation in experimental and clinical epilepsy and the effects of sodium valproate and vitamin E on these processes. Neurosciences, 1992, 18, 123-130.
26. Śmigielska-Kuzia J, Sobaniec W: Brain metabolic profile obtained by proton magnetic resonance spectroscopy HMRS in children with Down syndrome. Adv Med Sci, 2007, 52, Suppl, 1, 183-187.
27. Śmigielska-Kuzia J, Sobaniec W, Kułak W: Evaluation of efficacy of piracetam in add-on treatment of partial epilepsy in children. In: 3rd European Congress of Epileptology. Warsaw, Poland, May 24-28, 1998. Eds. Majkowski J, Owczarek K, Zwoliński P, Monduzzi Ed., Bologna, 1998, 427-431.
28. Śmigielska-Kuzia J, Sobaniec W, Kułak W, Zawada B, Paszko G, Boćkowski L: Antioxidant enzymes and lipid peroxides in children with Down syndrome. J Pediatr Neurol, 2007, 5, 117-120.
29. White NS, Alkire MT, Haier RJ: A voxel-based morphometric study of nondemented adults with Down syndrome. Neuroimage, 2003, 20, 393-403.
30. Wisniewski KE: Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet Suppl, 1990, 7, 274-281.
31. Zigman W, Schupf N, Haveman M, Silverman W: The epidemiology of Alzheimer disease in intellectual disability: results and recomendations from an international conference. J Intellect Disabil Res, 1997, 41, 76-80.